Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.77 USD
Change Today -0.235 / -3.36%
Volume 1.1M
As of 1:44 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

accuray inc (ARAY) Snapshot

Open
$7.13
Previous Close
$7.00
Day High
$7.16
Day Low
$6.74
52 Week High
04/13/15 - $10.01
52 Week Low
10/30/14 - $5.99
Market Cap
530.6M
Average Volume 10 Days
2.1M
EPS TTM
$-0.58
Shares Outstanding
78.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACCURAY INC (ARAY)

accuray inc (ARAY) Related Businessweek News

No Related Businessweek News Found

accuray inc (ARAY) Details

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. Accuray Incorporated markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors in Europe, Japan and rest of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.

1,026 Employees
Last Reported Date: 08/29/14
Founded in 1990

accuray inc (ARAY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $637.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $293.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $368.1K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $330.6K
Compensation as of Fiscal Year 2014.

accuray inc (ARAY) Key Developments

Accuray Incorporated Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015; Provides Earnings Guidance for the Fiscal Ending June 30, 2015

Accuray Incorporated announced unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2015. Revenue was $97.5 million, which was relatively flat from $97.1 million in the prior fiscal year's comparable quarter. The company reported third quarter net loss of $2.97 million or $0.04 loss per share, compared with the prior-year period's $4.7 million or $0.06 loss per share. Income from operations was $1,172,000 against loss of $475,000 a year ago. Loss before provision for income taxes was $2,446,000 against $3,787,000 a year ago. Adjusted EBITDA was $9,886,000 against $7,819,000 a year ago. For the nine months, total net revenue was $278,051,000, loss from operations was $17,691,000, loss before provision for income taxes was $32,298,000 and net loss was $34,609,000 or $0.44 per basic and diluted share against total net revenue of $267,419,000, loss from operations of $13,477,000, loss before provision for income taxes of $23,024,000 and net loss of $25,639,000 or $0.34 per basic and diluted share a year ago. Adjusted EBITDA was $5,132,000 against $10,778,000 a year ago. The company now expects fiscal ending June 30, 2015 revenue of $375 million to $385 million, down from the previous guidance of $390 million to $410 million. This would imply fourth quarter revenues of $97 million to $107 million and would produce full year revenue growth rates of 2% to 4% as reported and 6% to 8% on a constant currency. It expects GAAP net loss of $36,975,000 to $39,975,000, amortization of intangibles of $8,000,000, depreciation of $11,775,000, interest expense, net of $16,200,000, provision for income taxes of $3,000,000 and adjusted EBITDA of $13,000,000 to $16,000,000. The adjusted EBITDA range would imply reported gross margins in the fourth quarter will be essentially the same as in the third quarter and operating expense growth that would be flat to up 2% compared to the fourth quarter of 2014.

Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software

Accuray Incorporated announced that it has signed an agreement with MIM Software Inc. to further develop adaptive therapy software for the TomoTherapy® and CyberKnife® product portfolios. The new software solution will leverage both Accuray and MIM technology. This is Accuray's second collaboration with MIM; the previous partnership led to the development of the first iPad-based treatment plan review capability, PlanTouch.

Accuray Incorporated to Showcase New CyberKnife® and TomoTherapy® Technologies At ESTRO 2015

Accuray Incorporated announced that the company will highlight new CyberKnife® and TomoTherapy® technologies at the European Society for Therapeutic Radiology and Oncology (ESTRO) meeting, booth #2100, in Barcelona, Spain, April 24 – 27, 2015. The CyberKnife and TomoTherapy Systems are used to treat cancerous and benign tumors throughout the body. Each system precisely targets the tumor, delivering the prescribed radiation dose, while minimizing exposure to nearby healthy organs and tissues. At ESTRO, Accuray will showcase: The new Delivery Analysis Software for the TomoTherapy System: added confidence for every patient, every fraction, through a new tool that provides unprecedented access to treatment delivery information. The InCise™ Multileaf Collimator for the CyberKnife M6™ System: improves treatment efficiency for a broader range of tumor types. An enhancedSynchrony® Respiratory Tracking System for the CyberKnife System: makes it even easier for clinicians to know they are precisely tracking and adjusting for moving targets. The new Delivery Analysis Software for the TomoTherapy System: Delivery Analysis for the TomoTherapy System recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), in conjunction with the CE Mark in the European Union. The Delivery Analysis software is a tool that leverages the architecture of the TomoTherapy System to provide unprecedented access to treatment delivery information. The software provides enhanced confidence in system performance before each treatment, and actionable insights to help ensure all treatments stay on track. A pre-treatment test of the multileaf collimator (MLC) checks for differences between expected and measured MLC performance using pulse-by-pulse detector signals. Additionally, an in-treatment analysis of each delivered fraction is generated from exit detector data. It allows physicians to see if a particular fraction was not delivered as expected and helps to clarify the nature of the issue that led to the dose miss observed. An enhanced Synchrony® Respiratory Tracking System for the CyberKnife System: The Synchrony System is the only clinically proven system that uses continual image guidance to automatically adjust the movement of the beam in synchronization with movement of the target volume. This new technology enables clinicians to: Improve their ability to track moving targets and minimize treatment margins; Confidently set up Synchrony Respiratory Tracking with just a few mouse clicks; Set up and treat moving targets, in particular lung cases, faster and more easily.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARAY:US $6.77 USD -0.235

ARAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Elekta AB kr78.00 SEK -0.70
Koninklijke Philips NV €25.19 EUR -0.25
Mitsubishi Heavy Industries Ltd ¥673.60 JPY +5.90
RaySearch Laboratories AB kr99.00 SEK +2.50
Varian Medical Systems Inc $86.87 USD -1.52
View Industry Companies
 

Industry Analysis

ARAY

Industry Average

Valuation ARAY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCURAY INC, please visit www.accuray.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.